Review of Diffuse large B cell lymphoma, pharmacological aspects of treatment and comparison of outcome between Pre-,Post Rituximab era
Review of Diffuse large B cell lymphoma, pharmacological aspects of treatment and comparison of outcome between Pre-,Post Rituximab era
Dátum
Szerzők
Kim, Gang Kyu
Folyóirat címe
Folyóirat ISSN
Kötet címe (évfolyam száma)
Kiadó
Absztrakt
Diffuse large B Cell lymphoma (DLBCL) is a type aggressive non-Hodgkin Lymphoma
(NHL). About 30% of patients who diagnosed NHL is DLBCL in both male and female. It is
divided into 3 major types which distinct by immunological characteristics. It shall shows
variable spectrum of prognosis and response to the treatment due to gene expression
variability. Nowadays Rituximab is the gold standard treatment of NHL which is targeting
monoclonal antibody of CD20 and it also shows good prognosis to DLBCL. Rituximab
containing chemotherapy regimen like R-CHOP shows relatively good response to DLBCL
compare to pre-rituximab era and in rituximab era, overall relative survival rate was
significantly increased compare to pre-rituximab era. Recently, further study about the
treatment that adjusted to the gene mutation is in progress.
Leírás
Kulcsszavak
Diffuse large B cell lymphoma, Rituximab, RCHOP